Cytokine Assay in Tears of Healthy Children and With Vernal Keratoconjunctivitis: Case Control Study and Monitoring of Cases at 6 Months

Overview

The ocular surface may be the seat of an inflammatory process in many pathology as vernal keratoconjunctivitis. It has been shown that inflammatory cytokines produced by the cells themselves and the constituent cells of the target organ, are the main factors that cause inflammation. The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects.

Full Title of Study: “Cytokine Assay in Tears of Healthy Children and With Vernal Keratocunjonctivitis: Case Control Study and Monitoring of Cases at 6 Months”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2015

Detailed Description

The ocular surface may be the seat of an inflammatory process in many pathology as vernal keratoconjunctivitis. It has been shown that inflammatory cytokines produced by the cells themselves and the constituent cells of the target organ, are the main factors that cause inflammation. The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects.

Interventions

  • Procedure: Cytokins assay in tears

Arms, Groups and Cohorts

  • vernal keratoconjunctivitis
    • The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjonctivitis and in control subjects
  • healthy children
    • The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects

Clinical Trial Outcome Measures

Primary Measures

  • Concentration of 40 cytokines in tears
    • Time Frame: at time 0
    • Comparaison of concentration of 40 cytokines in tears between healthy children and children with vernal keratoconjunctivitis

Secondary Measures

  • Validation of normal range of cytokines in tears of healthy children
    • Time Frame: at 6 month
  • Modification of the inflammatory profile according to the clinical severity and treatment
    • Time Frame: at 6 month

Participating in This Clinical Trial

Inclusion Criteria

  • Childrens between 3 and 18 years
  • Affiliated at system of French social security
  • Signed by the holders of parental authority of the sheet and written consent to participate in this study
  • First consultation at Clermont-Ferrand Hospital for vernal keratocunjunctivitis

Exclusion Criteria

  • Subject suffering from acute or chronic eye disease in which the physician investigator resound with the results: uveitis, glaucoma, retinopathy
  • Subject who had undergone eye surgery
  • Subject having an infection the day of collection: ENT, digestive, urinary
  • Subject with cancer, mental illness or any other condition in which the physician investigator sound informed consent and / or the results
  • Pregnant subject
  • Subject with contact lenses
  • Subject who judged by the investigating physician not enough cooperating to allow a safe collection

Gender Eligibility: All

Minimum Age: 3 Years

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Hospital, Clermont-Ferrand
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Frédéric CHIAMBARETTA, Principal Investigator, University Hospital, Clermont-Ferrand
  • Overall Contact(s)
    • Patrick LACARIN, 04 73 75 11 95, placarin@chu-clermontferrand.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.